Panelists discuss how health care providers can promote medication adherence by moving beyond labeling patients as noncompliant, instead investigating root causes such as adverse effects, financial toxicity, or forgetfulness, while emphasizing the importance of building trusting relationships, involving caregivers as accountability partners, and creating personalized solutions that address each patient's specific barriers to maintaining their treatment regimen.

Panelists discuss how medication adherence significantly impacts chronic myeloid leukemia (CML) treatment outcomes, with research showing even small differences between 90% and 95% adherence to tyrosine kinase inhibitor (TKI) therapy can substantially affect molecular response rates, particularly during the critical first year of treatment, which largely determines future outcomes including potential treatment-free remission.

Early trial data show 13.3% objective response with avutometinib, abemaciclib, and fulvestrant in HR+/HER2– breast cancer resistant to CDK4/6 inhibitors.

A registered nurse gives best practices for use of subcutaneous daratumumab in multiple myeloma.

The FDA granted a complete response letter with no safety concerns for the new drug application for TLX101-CDx’s use in glioma imaging.

New data show strong overall survival rates, building on previously reported outcomes with efti plus pembrolizumab for head and neck squamous cell carcinoma.

Early-phase LUPER trial results suggest the lurbinectedin/pembrolizumab combination may benefit patients with relapsed small cell lung cancer.

Adagrasib shows early signs of activity and tolerability in patients with STK11/KRAS G12C–mutated non–small cell lung cancer.

KN026 plus chemotherapy improved PFS in patients with previously treated HER2-positive advanced gastric or GEJ cancer.

Subcutaneous daratumumab makes treatment a faster and more tolerable process for patients with multiple myeloma, according to an expert.

Final data from the phase 3 ALCYONE trial support frontline use of daratumumab-based therapy for patients with transplant-ineligible newly diagnosed multiple myeloma.

Approvals in oncology during April included treatments for breast cancer, colorectal cancer, and more.

Cretostimogene grenadenorepvec showed complete response across subgroups in patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer.

Panelists discuss how patient education plays a crucial role in ensuring adherence to tyrosine kinase inhibitor (TKI) therapy by building trust through clear explanations of medications and expected adverse effects, tailoring information to individual patients, involving caregivers when appropriate, and emphasizing that education must continue throughout the patient's lifelong treatment journey as part of a collaborative team approach.

Panelists discuss how establishing trust and open communication with patients with chronic myeloid leukemia (CML) is crucial for treatment adherence, emphasizing the importance of asking specific questions about adverse effects rather than general inquiries, acknowledging that patients may feel reluctant to mention problems due to feeling "blessed" to have life-saving medication, and ultimately ensuring these conversations happen to prevent routine visits from missing quality-of-life issues.

The selective CDK2 inhibitor INX-315 has been given FDA fast track designation for use in CCNE1-amplified, platinum-resistant ovarian cancer.

Oncology nurses can encourage clinical trial enrollment for patients with anaplastic thyroid cancer, a rare and aggressive cancer type.

A ready-to-dilute formulation of thiotepa has been approved by the FDA for use in breast and ovarian cancers.

A network meta-analysis suggests zanubrutinib may offer improved efficacy over other BTK inhibitors for patients with high-risk relapsed/refractory CLL.

Nurse practitioners and physician assistants can advocate to play a number of roles in oncology research, including primary investigators.

AYA Cancer Awareness Month offers an opportunity for nurses to go further in supporting AYAs with cancer.

The FDA’s decision not to grant breakthrough designation or accelerated approval for itolizumab in acute GVHD has led to the discontinuation of the pivotal phase 3 EQUATOR trial.

Both those receiving either expected or less-than-expected starting dosages of ruxolitinib for myelofibrosis treatment reduced daily dosages over 12 months.

Findings from the phase 1 BrainChild-03 trial support breakthrough designation for BCB-276 for pediatric diffuse intrinsic pontine glioma.

The FDA approved penpulimab-kcqx combination and monotherapy for non-keratinizing nasopharyngeal carcinoma.